D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Esophageal ulceration induced by zidovudine.
TL;DR: Esophageal injury induced by oral medication is well documented by over 300 case reports and in two major studies (1, 2), age, posture, volume of fluid chaser, and dissolution pH of the stomach after oral medication are well documented.
Journal ArticleDOI
Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients.
Myat T. Kyaw,Lindsay Hurren,Louise Evans,Denis J. Moss,David A. Cooper,Elizabeth M. Benson,Donald Esmore,Tom B. Sculley +7 more
TL;DR: A higher prevalence of infection with B-type EBV in HIV+ patients, than had been found previously by an analysis of spontaneously generated lymphoblastoid cell lines, is demonstrated.
Journal ArticleDOI
Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration.
Stephany N. Duda,Amanda M. Farr,Mary Lou Lindegren,Meridith Blevins,C. William Wester,Kara Wools-Kaloustian,Didier K. Ekouevi,Matthias Egger,Jennifer Hemingway-Foday,David A. Cooper,Richard D. Moore,Catherine C. McGowan,Denis Nash +12 more
TL;DR: This work sought to describe capacity in HIV programmes in seven regions worldwide and found that in most of the regions, the capacity to deliver comprehensive care was low.
Journal ArticleDOI
Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy
Jason V. Baker,Jason V. Baker,Jacqueline Neuhaus,Daniel Duprez,David A. Cooper,Jennifer F Hoy,Lewis H. Kuller,Fiona C Lampe,Angelike P. Liappis,Nina Friis-Møller,James D. Otvos,Nicholas I. Paton,Russell P. Tracy,James D. Neaton +13 more
TL;DR: These findings suggest that activation of inflammatory pathways contribute to HIV-associated changes in HDL following ART initiation, to a degree that depends on the degree of inflammation present at entry.
Journal ArticleDOI
Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options
TL;DR: Recently, studies have shown that non-nucleoside reverse transcriptase inhibitors, such as efavirenz or nevirapine, in combination with two nucleoside analogues have an antiretroviral potency comparable to protease inhibitor containing regimens.